Resources
Uploaded
Jan 5, 2010
One of the topics that frequently occurs in the clinic, and that patients often ask about, is the situation in which there is some suggestion of slight progression.
Cetuximab (Erbitux) for Advanced NSCLC: Promising Results, But is it Ready for Prime Time?
(93.5 KB)
Uploaded
Jan 5, 2010
There has been quite a lot of discussion recently about the EGFR tyrosine kinase inhibitors (TKIs), erlotinib (Tarceva) and gefitinib (Iressa). Recently however the final results of the FLEX trial ...
more
Uploaded
Jan 5, 2010
Avastin (bevacizumab), an antiangiogenic agent that works by blocking the blood vessel stimulating factor vascular endothelial growth factor (VEGF), has already been FDA approved and commercially a...
more
Uploaded
Jan 5, 2010
We know far too little about the best way to treat older patients with NSCLC, that lung cancer, like many other cancers, is a disease highly related to advanced age.
